Prudential Financial Inc. Sells 4,185 Shares of Masimo Co. (NASDAQ:MASI)

Prudential Financial Inc. decreased its holdings in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 63.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,451 shares of the medical equipment provider's stock after selling 4,185 shares during the quarter. Prudential Financial Inc.'s holdings in Masimo were worth $405,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in MASI. Vanguard Group Inc. raised its stake in shares of Masimo by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider's stock valued at $758,182,000 after purchasing an additional 66,215 shares during the period. State Street Corp increased its position in shares of Masimo by 0.7% during the third quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider's stock valued at $191,837,000 after buying an additional 10,179 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Masimo by 1.5% in the third quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider's stock worth $105,741,000 after buying an additional 11,984 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Masimo by 2.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 377,836 shares of the medical equipment provider's stock valued at $62,456,000 after acquiring an additional 7,808 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Masimo by 0.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 373,705 shares of the medical equipment provider's stock valued at $61,773,000 after acquiring an additional 1,522 shares during the period. Hedge funds and other institutional investors own 85.96% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several analysts have issued reports on MASI shares. Raymond James increased their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research note on Friday, December 27th. Wells Fargo & Company increased their price objective on Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Piper Sandler boosted their target price on Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $194.80.

Insider Buying and Selling at Masimo

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the business's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now directly owns 16,581 shares of the company's stock, valued at $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.70% of the company's stock.

Masimo Price Performance

NASDAQ:MASI traded up $0.14 during midday trading on Tuesday, hitting $153.75. The company had a trading volume of 45,608 shares, compared to its average volume of 653,959. The stock's fifty day moving average price is $170.11 and its 200-day moving average price is $164.63. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $8.31 billion, a PE ratio of 105.79 and a beta of 1.28.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. The firm had revenue of $600.70 million during the quarter, compared to analysts' expectations of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. As a group, research analysts expect that Masimo Co. will post 4.1 earnings per share for the current year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.